Zogenix, Inc.
NASDAQ: ZGNX
$21.29
+$0.29 (+1.4%)
Closing price October 23, 2020
Tuesday's top analyst upgrades and downgrades included Crocs, Gap, GW Pharmaceuticals, Lowe's Companies, Merck, Nio, Palo Alto Networks, Phillips 66, Starbucks and Vital Farms.
2 months ago
Last Updated: 2 months ago
Thursday was a breakout day for a few biotech companies. Some made absolutely massive runs, while others fell off a cliff.
1 year ago
Last Updated: 8 months ago
Zogenix shares were crushed on Tuesday after the firm provided an update from the FDA regarding Fintepla for the treatment of seizures associated with Dravet syndrome.
1 year ago
Last Updated: 2 months ago
The top analyst upgrades, downgrades and initiations seen on Friday include Apple, Caterpillar, Costco, GW Pharmaceuticals, NXP Semiconductors, Southwest Airlines, Teva Pharmaceutical, Ulta Beauty...
2 years ago
Last Updated: 9 months ago
Zogenix shares made a solid gain on Thursday after the company announced positive results from its late-stage seizure trial.
2 years ago
Last Updated: 9 months ago
The top analyst upgrades, downgrades and other research calls from Monday include AECOM, Ciena, Evoqua Water Tech, Funko, GlaxoSmithKline and Square.
2 years ago
Last Updated: 7 months ago
Zogenix saw its shares more than double early on Friday after the company reported positive top-line results from its most recent late-stage trial in the treatment of Dravet syndrome.
3 years ago
Last Updated: 9 months ago
All three of these specialty pharmaceutical stocks come with a fair share of risk but provide big upside potential as well.
4 years ago
Last Updated: 9 months ago
Aggressive traders looking for solid ideas with big upside from all over Wall Street will like a new research note from Stifel, which features four stocks to buy with huge potential.
5 years ago
Last Updated: 5 years ago
Stocks are still very close to all-time highs, and this bull market is now six years old. It turns out that some stocks made unusual moves last week.
5 years ago
Last Updated: 5 years ago
Zogenix has announced an agreement for the sale of its Zohydro ER (hydrocodone bitartrate) business to Pernix for $100 million.
5 years ago
Analysts who cover low-priced and small-cap stocks often predict upside of 50%, 100% or much more. You just don't see calls like that in Dow and S&P 500 stocks.
6 years ago
Last Updated: 6 years ago
Oppenheimer's official rating on Zogenix remains Outperform, but what stands out is that the $2.50 price target implies that shares can more than double.
6 years ago
Last Updated: 6 years ago
Zogenix has traded like a company that is about to implode. Its highly controversial Zohydro has been getting inquiries into how it was approved for marketing despite an FDA panel being against the...
6 years ago
Shares of Zogenix fell as much as 26% on Wednesday after a rival pharmaceutical company said it will seek regulatory approval of a tamper-proof version of Zogenix's powerful new pain drug.
6 years ago